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Metastases account for 90% of cancer-associated deaths1, so it is critical 
to understand the mechanisms that mediate this process. The plastic 
nature of the epigenetic landscape of tumoral cells2–4 contributes to 
cancer progression and metastasis. In this regard, transcriptional 
silencing associated with promoter CpG island hypermethylation5–8 
has been linked to tumor invasion. However, we know little about the 
epigenetic events involved in melanoma metastasis9,10, a deficit that 
is of particular concern because cutaneous melanoma has a growing 
incidence and mortality11. In the clinical setting, it is necessary to 
find molecular biomarkers for predicting whether metastatic disease 
will develop or for determining prognosis; in addition, it is neces-
sary to determine histopathological features such as Breslow stage 
or the presence of ulceration12,13. Despite the introduction of small-
molecule drugs that target kinases, such as BRAF and MEK inhibi-
tors, and immunological treatments14–16, little improvement in the 
survival of individuals with disseminated disease has been achieved. 
Thus, there is a need to discover melanoma markers that are able to 
identify subjects with the most pro-metastatic forms of the disease. 
Most importantly, it would be optimal to use knowledge of molecular 
mechanisms of melanoma metastasis to identify therapeutic targets. 
By using epigenomic approaches, combined with functional in vitro 
and in vivo data and clinical cohorts of melanoma, we show how the 
DNA hypomethylation-associated reactivation of the Rab GTPase 
activating protein TBC1D16 isoform may be such a candidate.
RESULTS
Identification of DNA methylation loci associated with metastasis
To identify DNA methylation-associated changes involved in 
the formation of metastatic melanoma, we analyzed cell lines 
derived from the primary tumor and the lymph node metastasis of 
the same individual. We first selected the primary melanoma cell 
line IGR39 and its paired metastasis cell line IGR37 (ref. 17). We 
obtained the DNA methylation profile of each sample using the 
Infinium HumanMethylation450 (450K) microarray18. We wanted 
to find genes that participate directly in metastasis, so we also 
hybridized additional pairs of primary and metastasis cell lines 
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Epigenetic activation of a cryptic TBC1D16 transcript 
enhances melanoma progression by targeting EGFR
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Alfonso Berrocal9, Fredrik Pontén10, Joost van den Oord11, William M Gallagher12, Dennie T Frederick13,  
Keith T Flaherty13, Ultan McDermott14, Paul Lorigan15, Richard Marais2 & Manel Esteller1,16,17
Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to 
metastasize. Here we study the contribution of epigenetic changes to the dissemination process by analyzing the changes that occur 
at the DNA methylation level between primary cancer cells and metastases. We found a hypomethylation event that reactivates a 
cryptic transcript of the Rab GTPase activating protein TBC1D16 (TBC1D16-47 kDa; referred to hereafter as TBC1D16-47KD) to 
be a characteristic feature of the metastatic cascade. This short isoform of TBC1D16 exacerbates melanoma growth and metastasis 
both in vitro and in vivo. By combining immunoprecipitation and mass spectrometry, we identified RAB5C as a new TBC1D16 target 
and showed that it regulates EGFR in melanoma cells. We also found that epigenetic reactivation of TBC1D16-47KD is associated 
with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.
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from two other malignancies: colon (SW480 (primary) and 
SW620 (metastasis)) and breast (MDA-MB-468PT (primary) and 
MDA-MB-468LN (metastasis)).
We analyzed 482,422 CpGs in the three paired cancer cell lines, in 
which we explored the probes with low dispersion (s.d. < 0.1) within 
the primary and metastatic groups (to identify common CpG meth-
ylation events involved in the metastasis in the three tumor types) and 
high dispersion between the groups (to identify common CpG sites 
that discriminated primary from metastases sites for all three tumor 
types). Using this approach, we obtained 2,620 CpG probes that dis-
tinguished between cell lines derived from primary or metastatic sites 
independently of the tumor type (Fig. 1a and Supplementary Data 1). 
To identify candidate genes with differential methylation, we imposed 
stringent criteria: we considered only CpG sites with a ≥70% change in 
CpG methylation level; the CpG had to be in a CpG island (differential 
methylation outside CpG islands is shown in Supplementary Data 2); 
the CpG had to be within ± 2,000 bp of the transcription start site; and 
the differential CpG methylation between primary and metastases 
had to occur in the three tumor types. Under these conditions, we 
identified only two candidate genes: TBC1 domain family member 
16 (TBC1D16)19,20, which loses CpG methylation in the metastatic 
cell lines compared with the primary cancer cells; and strawberry 
notch homolog 2 (SBNO2)21, which gains CpG methylation. We then 
merged the DNA methylation data with the transcriptional profiles 
obtained from an Affymetrix GeneChip Human Genome U133 Plus 
2.0 microarray hybridization (melanoma) or data available from Gene 
Expression Omnibus (breast and colon). For SBNO2 there was no 
correlation between methylation and expression (Fig. 1b). However, 
TBC1D16 was hypermethylated and downregulated in the primary 
cancer cell lines and overexpressed and unmethylated in the paired 
corresponding metastatic cells (Fig. 1b). Thus, the DNA demeth-
ylation-associated re-expression of TBC1D16 in the metastatic cells 
became our main focus of interest.
TBC1D16-47KD epigenetic activation in metastatic melanoma
The loss of methylation from the metastatic cells occurred in the CpGs 
located around the transcription start site of two short isoforms of 
TBC1D16 (TBC1D16-45KD and TBC1D16-47KD) (Fig. 1c), whereas 
the CpGs surrounding the long isoform (TBC1D16-86KD) remained 
unmethylated in all six cell lines (Supplementary Fig. 1). Western 
blot analyses confirmed that TBC1D16 demethylation was associated 
with reactivation of TBC1D16-47KD expression (the short isoform 
recognized by the only available antibody), whereas TBC1D16-86KD 
expression remained unaltered in the three paired cancer cell lines 
(Fig. 1d). RT-PCR assays designed to recognize TBC1D16-47KD 
(Fig. 1e) and TBC1D16-45KD (Supplementary Fig. 2a,b) confirmed 
the described pattern and a DNA demethylating agent restored 
their expression, without affecting TBC1D16-86KD (Supplementary 
Fig. 3a). We focused our subsequent studies on TBC1D16-47KD 
because it is readily detected and shares high homology with the other 
short isoform (TBC1D16-45KD, 98% homologous), which behaves in 
a similar fashion in all performed assays (Supplementary Fig. 2)
We established a mechanistic link between TBC1D16-47KD 
hypomethylation and transcript reactivation by studying the 
microphthalmia-associated transcription factor (MITF), a master 
regulator of melanocyte development and a recognized oncogene14. 
The TBC1D16-47KD CpG island contains a MITF E-box binding site 
(Supplementary Fig. 4a). Chromatin immunoprecipitation revealed 
that MITF binds to the unmethylated CpG island in IGR37 cells, but 
not to the methylated sequence of IGR39 (Supplementary Fig. 4b). 
Reporter assays demonstrated that the E-box of TBC1D16-
47KD was required for its regulation by MITF (Supplementary 
Fig. 4c). Importantly, depletion of MITF mediated by small interfer-
ing RNA in unmethylated cells downregulated TBC1D16-47KD, as 
well as TBC1D16-86KD, which contains two E-boxes in its promoter 
(Supplementary Fig. 4d).
We found TBC1D16-47KD methylation in the normal counterparts 
of the analyzed malignancies (Supplementary Fig. 5a) and absence 
or minimal levels of the transcript (Fig. 1e). Data mining of TCGA 
450K DNA methylation data confirmed hypermethylation of these 
CpGs in all normal samples, with two exceptions: central nervous 
system and embryonic stem cells (Supplementary Fig. 5b). Bisulfite 
genomic sequencing confirmed the unmethylated status in gray and 
white brain matter and we detected TBC1D16-47KD expression 
(Supplementary Fig. 5c,d). Thus, TBC1D16-47KD probably has a 
physiological role in the embryo and the neuronal lineage, whereas 
it remains densely methylated and silenced in the remaining tissues.
TBC1D16-47KD promotes melanoma progression
We next pursued cellular approaches to demonstrate that the epige-
netic reactivation of this transcript contributed to melanoma progres-
sion. We created stable knockdowns of TBC1D16-47KD by the short 
hairpin RNA (shRNA) method in TBC1D16-expressing and unmeth-
ylated melanoma metastasis-derived cells (IGR37). Upon shRNA-
mediated depletion of TBC1D16-47KD from IGR37 cells (Fig. 2a and 
Supplementary Fig. 6a), we observed lower cell proliferation (Fig. 2b). 
We obtained similar results when we knocked-down TBC1D16-47KD 
in the metastatic breast and colon cells (Supplementary Fig. 6b). 
Conversely, ectopic expression of TBC1D16-47KD in IGR39 increased 
cellular proliferation (Fig. 2c). TBC1D16-47KD transfection did not 
affect TBC1D16-86KD expression (Supplementary Fig. 3b). shRNA-
mediated depletion of TBC1D16-47KD from IGR37 reduced invasion 
capacity according to XCELLigence real-time cell analysis22 (Fig. 2d). 
Conversely, TBC1D16-47KD transfection in IGR39 increased 
invasion capacity (Fig. 2d).
We translated these results to an in vivo setting in athymic nude mice. 
Tumors originating from TBC1D16-47KD shRNA-downregulated 
IGR37 cells had smaller volumes and weighed less (Fig. 2e) than those 
derived from scrambled-shRNA cells. TBC1D16-47KD orthotopic-
depleted tumors were also smaller and lighter than the scrambled 
shRNA-derived tumors (Fig. 2f). Breast and colon cancer cells showed 
similar results (Supplementary Fig. 6c). TBC1D16-86KD expression 
was not affected (Supplementary Fig. 6c). We also studied the poten-
tial contribution of TBC1D16-47KD to metastasis. After confirming 
that IGR37 cells had higher metastatic potential than IGR39 (Fig. 2g), 
we studied the effect of TBC1D16-47KD depletion in IGR37. We 
found that although 88% scrambled-orthotopic tumors were able to 
metastasize to the lymph nodes, only 25% of the TBC1D16-47KD 
orthotopic-depleted tumors had this ability (Fisher’s exact test, P = 0.04) 
(Fig. 2h). With respect to blood dissemination, none of the eight 
orthotopic TBC1D16-47KD shRNA-downregulated tumors yielded 
distant metastasis, whereas there were lung metastases in 38% of the 
scrambled-orthotopic tumors (Fig. 2i). Conversely, ectopic expres-
sion of TBC1D16-47KD in IGR39 increased its metastatic potential 
(Fig. 2i). We also used an additional model of metastasis: direct spleen 
injection. We observed that scrambled-shRNA IGR37 cells induced a 
higher formation of liver metastases than TBC1D16-47KD shRNA-
depleted IGR37 cells (Student’s t-test, P < 0.001) (Fig. 2j).
We extended our analysis to an additional paired primary and metas-
tasis melanoma model derived from the same individual: WM115 
©
20
15
N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
a r t i c l e s
nature medicine  advance online publication 
(primary) and WM266.4 (metastasis). We observed hypomethylation-
associated reactivation of TBC1D16-47KD in WM266.4 cells, whereas 
WM115 showed methylation and silencing (Supplementary Fig. 7a). 
TBC1D16-47KD ectopic expression in WM115 increased melanoma 
growth and progression (Supplementary Fig. 7b). Conversely, 
TBC1D16-47KD depletion by shRNA from WM266.4 cells had the 
opposite effects (Supplementary Fig. 7c). We also used two additional 
melanoma cell lines: WM793, derived from a primary melanoma, 
in which we found methylated and repressed TBC1D16-47KD; 
and SK-MEL-28, derived from a melanoma metastasis with an 
unmethylated and expressed TBC1D16-47KD (Supplementary 
Fig. 8a). TBC1D16-47KD transfection in WM793 increased 
growth and progression (Supplementary Fig. 8b). Conversely, 
TBC1D16-47KD shRNA-mediated depletion in SK-MEL-28 had the 
opposite effects (Supplementary Fig. 8c).
TBC1D16-47KD regulates Rab GTPases and EGFR activation
TBC1D16 is a member of the family of proteins containing the 
Tre2/Bub2/Cdc16 (TBC) domain, which are associated with cell 
signaling and intracellular receptor trafficking19,20. These TBC 
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Figure 1 DNA hypomethylation-associated transcriptional  
activation of a TBC1D16 cryptic isoform in metastatic  
cancer cells. (a) DNA methylation heatmap clustering  
of 2,620 CpG sites showing DNA methylation events  
that distinguish primary (IGR39, MDA-MB-468PT and SW480)  
or metastatic-derived cell lines (IGR37, MDA-MB-468LN and SW620).  
(b) Representation of the correlation between DNA methylation microarray  
data and gene expression microarray values for TBC1D16 and SBNO2.  
Expression is represented as the average intensity of three probes for  
TBC1D16 and two probes for SBNO2. (c) Genomic structure of TBC1D16.  
Transcription start sites (TSSs) of the isoforms are denoted by small black  
arrows. Locations of CpG islands (green bars) and designed bisulfite sequencing  
primers (black horizontal arrows) are shown. Bisulfite genomic sequencing was carried out in eight  
individual clones. The presence of a methylated or unmethylated cytosine is indicated by a black or white  
square, respectively. (d) Protein expression levels for the TBC1D16-47KD and TBC1D16-86KD isoforms analyzed by western blot in the paired  
primary/metastasis cancer cell lines. (e) Conventional (top) and quantitative RT-PCR (middle) analyses of TBC1D16 (47 kDa) expression in paired  
primary and metastasis cancer cell lines and normal tissues. Bottom, reactivation of the TBC1D16 (47 kDa) transcript upon use of the DNA 
demethylating agent 5-aza-2′-deoxycytidine (aza). NS, nonsignificant; *P < 0.05; **P < 0.01, using Student’s t-test. Error bars show means ± s.d.
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Figure 2 TBC1D16-47KD enhances melanoma progression in vitro and in vivo. (a) Western blot of TBC1D16-47KD shRNA interference in IGR37.  
(b) Colony formation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays in TBC1D16-47KD shRNA-depleted IGR37 cells. 
Values derived from two experiments with 12 replicates (mean ± s.d.); significance according to 10,000-permutation t-test with Holm correction.  
(c) Cellular proliferation upon TBC1D16-47KD ectopic expression in IGR39. (d) Invasion capacity upon shRNA-mediated depletion in IGR37 and 
TBC1D16-47KD transfection in IGR39 cells. (e) Top, tumor volume in subcutaneous implanted shRNA TBC1D16-47KD-depleted IGR37. Bottom, 
TBC1D16-47KD and TBC1D16-86KD protein levels (22 d; n = 5 for group). Right, illustrative samples obtained at the end point and mean ± s.d. 
weights. (f) Left, orthotopic volumes from TBC1D16-47KD shRNA-depleted IGR37 cells. Bottom, TBC1D16-47KD and TBC1D16-86KD protein levels 
(30 d, n = 8 for group). Right, illustrative endpoint tumor samples and mean ± s.d. tumor weights. (g) Left, model of orthotopic melanoma implantation 
for studying metastasis. Right, H&E staining of lymph nodes showing metastases (M). Percentage of metastatic lymph nodes in orthotopics derived  
from IGR37 (eight mice) and IGR39 (six mice). (h) H&E staining. Percentage of metastatic lymph nodes upon TBC1D16-47KD shRNA depletion in 
IGR37-derived orthotopics (eight mice). (i) H&E staining of lungs showing metastases. Percentage of metastases upon TBC1D16-47KD depletion in 
IGR37-derived orthotopics (eight mice) (left) and in IGR39 (eight mice) tumors with TBC1D16-47KD ectopic expression (right). (j) Number of liver 
metastases (black stars) upon direct spleen injection of TBC1D16-47KD shRNA-depleted IGR37 cells (ten mice). NS, nonsignificant; *P < 0.05;  
**P < 0.01, ***P < 0.001; Student’s t-test. Error bars show means ± s.d.
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domains form the catalytic core of many GTPase-activating proteins 
that regulate Rab GTPases23. Here, using co-immunoprecipitation, 
we have confirmed the described direct binding of TBC1D16-47KD 
with RAB27A and RAB4A19,20 (Fig. 3a).
To identify targets involved in melanoma by TBC1D16-47KD 
epigenetic reactivation, we performed mass spectrometry (MS) to 
compare the immunoprecipitates obtained from empty vector and 
TBC1D16-FLAG-(47KD)-transfected IGR37 cells (Fig. 3b). We iden-
tified 39 proteins in the TBC1D16-47KD-immunoprecipitated sample 
(Supplementary Table 1). The first hit was TBC1D16-47KD itself, 
showing that the designed MS workflow was efficient. Notably, we 
identified a new RAB binding partner for TBC1D16-47KD: RAB5C 
(Fig. 3c). Co-immunoprecipitation confirmed the direct binding of 
TBC1D16-47KD to RAB5C (Fig. 3d), and immunofluorescence dem-
onstrated the colocalization of both proteins (Fig. 3e).
The reported role of TBC1D16 in enhancing EGF-stimulated 
EGFR degradation mediated by RAB4A20 and the action of RAB5C 
in the EGFR downstream pathway24 prompted us to examine 
whether TBC1D16-47KD exerted an EGFR regulator effect medi-
ated by RAB5C. First, we observed that TBC1D16-47KD enhanced 
RAB5C GTPase activity, and thus counteracted RAB5C function, 
in a concentration-dependent manner (Supplementary Fig. 9a). 
In this regard, RAB5C shRNA-mediated depletion in IGR37 cells 
had the opposite effect to TBC1D16-47KD depletion: enhanced 
growth and invasion capacity (Supplementary Fig. 9b) and reduced 
EGFR expression (Supplementary Fig. 9c). Second, we overexpressed 
RAB5C in IGR37 cells and found that it increased membrane– 
associated EGFR (Supplementary Fig. 9d), as it occurs with 
RAB4A20. Third, we found that IGR39 (TBC1D16-47KD methyl-
ated) had a large amount of EGFR and its phosphorylated Y1068 
form, whereas IGR37 cells (TBC1D16-47KD unmethylated) had 
minimal amounts of EGFR and a hypophosphorylated status (Fig. 3f). 
We observed the same pattern in the paired breast-colon primary- 
metastasis cells (Supplementary Fig. 9e). Finally, we proceeded 
with IGR37 serum starvation followed by EGF stimulation. 
Downregulation of TBC1D16-47KD induced higher levels of EGFR 
and phospho-EGFR than in control cells (Fig. 3g). We obtained simi-
lar results upon TBC1D16-47KD depletion in SK-MEL-28 (another 
unmethylated melanoma cell line) (Supplementary Fig. 8d). 
Conversely, TBC1D16-47KD ectopic expression in IGR39 cells 
decreased EGFR (Supplementary Fig. 9f). We observed identical 
findings upon TBC1D16-47KD transfection in WM793, another 
methylated and silenced melanoma cell line, (Supplementary Fig. 8d). 
Importantly, we validated these findings in the unmethylated 
metastasis-derived WM266.6 cell line, which showed low levels of 
EGFR, whereas we observed high levels in the WM115 methylated 
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Figure 3 TBC1D16-47KD regulates Rab GTPases and EGFR activation in melanoma cells. (a) Co-immunoprecipitation experiments show the interaction 
of TBC1D16-47KD with the Rab GTPases, RAB4A and RAB27A. Immunoprecipitation (IP) and western blotting (WB) were carried out using anti-FLAG 
and anti-RAB antibodies. Normal mouse IgG was used as a negative control. UB, unbound fraction; B, bound fraction. (b) Strategy used to identify 
TBC1D16-47KD novel interacting RABs based on MS analysis comparing the protein immunoprecipitates obtained in IGR37 cells from the empty 
vector–transfected condition versus the TBC1D16-47KD-FLAG–transfected cells. (c) Data from a representative RAB5C peptide identified by MS.  
(d) Co-immunoprecipitation experiments confirmed the interaction between TBC1D16-47KD and RAB5C. Immunoprecipitation and western blotting 
were performed using anti-FLAG and anti-RAB5C. UB, unbound fraction; B, bound fraction. (e) Examples of multicolored immunofluorescence images show 
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cells (Supplementary Fig. 7d). Transfection of TBC1D16-47KD in 
WM115 induced EGFR downregulation (Supplementary Fig. 7e).
These results suggest that the epigenetically reactivated TBC1D16-
47KD transcript, acting through RABs, is able to reduce EGFR activity 
in metastatic cells.
TBC1D16-47KD increases sensitivity to BRAF and MEK inhibitors
The observed EGFR downregulation and its hypophosphorylated 
status upon TBC1D16-47KD DNA hypomethylation-mediated re-
expression prompted us to determine whether it affects drug sensitiv-
ity. BRAF inhibitors have clinical benefits in melanomas with mutant 
BRAF14,15, and although resistance to these drugs emerges, it can be 
mediated through pathways involving EGFR25,26 and PI3K/AKT27,28 
activation. Thus, we examined whether epigenetic reactivation of 
TBC1D16-47KD conferred distinct responses to BRAF inhibitors and 
also to MEK inhibitors, other targetable proteins in that pathway.
In our original model of the paired primary and metastasis 
melanoma cells, IGR39 and IGR37, both share the same BRAF activat-
ing mutation (V600E) and, thus, it is thought they share a high drug 
sensitivity. However, IGR37 cells, with a less active EGFR, were more 
sensitive to the BRAF inhibitor dabrafenib than IGR39 cells, with 
highly active EGFR (Fig. 4a). Furthermore, TBC1D16-47KD shRNA 
depletion in IGR37 cells induced higher resistance to dabrafenib 
(Fig. 4b). Orthotopic tumors from IGR39 (Fig. 4c) were resistant 
to the BRAF inhibitor. Tumors from TBC1D16-47KD scrambled 
IGR37 cells were more responsive to the BRAF inhibitor than IGR37 
TBC1D16-47KD shRNA-depleted tumors (Fig. 4d).
We found the same pattern for MEK inhibitors: IGR37 epigeneti-
cally reactivated by TBC1D16-47KD was more sensitive to AZD6244 
(selumetinib) and CI-1040 than TBC1D16-47KD methylated IGR39 
(Fig. 5a). Downregulation of TBC1D16-47KD in IGR37 increased 
resistance to MEK inhibitors (Fig. 5b). We extended these observations 
by comparing the TBC1D16-47KD methylation status in 36 additional 
melanoma cell lines (Supplementary Data 3) with the corresponding 
sensitivity to MEK inhibitors29. Therein, we observed that TBC1D16-
47KD unmethylated status was also associated with sensitivity to 
AZD6244 and CI-1040 (Student’s t-test, P = 0.0110 and P = 0.0015, 
respectively) (Fig. 5c).
We complemented these findings using the two described 
melanoma cell lines that also harbor a BRAF mutation: WM793 
(primary, TBC1D16-47KD methylated) and SK-MEL-28 (metastasis 
TBC1D16-47KD unmethylated) (Supplementary Fig. 8). SK-MEL-28 
cells showed low levels of EGFR, whereas we saw high levels in 
WM793 cells (Supplementary Fig. 8d). Thus, the SK-MEL-28 cells 
were more sensitive to the BRAF and MEK inhibitors than WM793 
cells (Fig. 5d). Furthermore, shRNA-depletion of TBC1D16-47KD 
in SK-MEL-28 cells triggered EGFR upregulation and increased 
resistance to BRAF and MEK inhibitors, whereas TBC1D16-47KD 
transfection in WM793 decreased EGFR levels (Supplementary 
Fig. 8d) and increased drug sensitivity (Supplementary Fig. 8e). We 
found the same patterns in the paired breast-colon primary-metastasis 
cells (Supplementary Fig. 10a). Bearing in mind that both long and 
short TBC1D16 isoforms have the ability to stimulate Rab4A GTPase 
activity20, we carried out TBC1D16-86KD knockdown to show that 
depletion was also associated with resistance to BRAF and MEK 
inhibitors (Supplementary Fig. 3c).
It is possible that the high levels of phosphorylated EGFR in 
TBC1D16-47KD methylated cells cause, upon treatment with BRAF 
and MEK inhibitors, a shift in cellular proliferation that depends on 
the PI3K/AKT pathway, which cannot be blocked by the described 
drugs27,28. Conversely, the TBC1D16-47KD unmethylated cells, with 
their low associated phospho-EGFR levels, cannot properly activate 
this alternative growth pathway to survive and are more sensitive 
to the BRAF and MEK inhibitors. We addressed this hypothesis by 
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Figure 4 Epigenetic reactivation of TBC1D16-47KD  
predicts response to BRAF inhibition. (a) MTT and  
sulforhodamine B (SRB) assays for IGR37  
(TBC1D16-47KD unmethylated and expressed)  
and IGR39 (TBC1D16-47KD methylated and  
repressed) cells upon the use of the BRAF inhibitor  
dabrafenib. Corresponding half-maximal inhibitory  
concentration (IC50) values are also shown.  
R = resistance to drug inhibition. Values are the  
mean ± s.e.m (n = 3 for each group). (b) MTT and  
SRB assays in TBC1D16-47KD shRNA-downregulated  
IGR37 cells upon the use of dabrafenib. Values are the mean ± s.e.m (n = 3 for each group). (c) Volume of TBC1D16-47KD methylated orthotopic 
tumors derived from IGR39 upon daily BRAF inhibitor (30 mg/kg) or vehicle treatment. Values are the mean ± s.d. (n = 5 for each group.) Right, 
representative images of the studied melanoma grafts. Tn/T0 (%), tumor size on day “n” in relation to day 0 of drug treatment. (d) Left, volume of 
TBC1D16-47KD unmethylated orthotopic tumors derived from scrambled shRNA IGR37 upon daily treatment with BRAF inhibitor (30 mg/kg) (n = 9) 
or vehicle (n = 5). Right, TBC1D16-47KD shRNA-depleted IGR37-derived orthotopic tumors (n = 7) are less responsive to the BRAF inhibitor than the 
shRNA scrambled IGR37-derived tumors. Tn/T0 (%), tumor size on day “n” in relation to day 0 of drug treatment. Values are the mean ± s.d. (n = 7 for 
each group). Significance was determined from a 10,000-permutation t-test with Holm correction of the difference between growth or volume curves. 
NS, nonsignificant; *P < 0.05; **P < 0.01, ***P < 0.001. Representative images of the studied melanoma grafts are shown.
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studying ERK (representative of the RAS/BRAF/MEK/ERK pathway) 
and AKT (representative of the PI3K/AKT pathway) activation. We 
observed that the MEK inhibitor blocked phosphorylation of ERK 
independently of TBC1D16-47KD methylation and expression status 
(Fig. 5e). However, the BRAF inhibitor only blocked ERK phospho-
rylation in the context of TBC1D16-47KD-unmethylated cells, such 
as IGR37 and SK-MEL-28 (Fig. 5f). Thus, there is an initial distinct 
sensitivity to these drugs targeting the RAS/BRAF/MEK/ERK 
pathway at different levels that is associated with TBC1D16-47KD 
methylation status. However, in addition, melanoma cells with a 
methylated TBC1D16-47KD show drug-resistance mechanisms 
that involve the PI3K/AKT pathway. After MEK and BRAF inhibitor 
treatment, we found that high levels of phospho-EGFR, associated 
with hypermethylated TBC1D16-47KD (IGR39, WM115 and 
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Figure 5 Epigenetic reactivation of TBC1D16-47KD predicts response to BRAF and MEK inhibitors by targeting two signaling pathways. (a) MTT 
and SRB assays in IGR37 and IGR39 cells upon treatment with MEK inhibitors (AZD6244 and CI-1040). Corresponding half-maximal inhibitory 
concentration (IC50) values are also shown. R = resistance to drug inhibition. (b) shRNA-mediated downregulation of TBC1D16-47KD induced higher 
resistance to MEK inhibitors compared with the shRNA-scrambled control cells. (c) TBC1D16-47KD CpG island unmethylated status is associated with 
enhanced sensitivity to MEK inhibitors in the Sanger panel of melanoma cell lines. y axis, drug IC50 values (natural log, µM); x axis, DNA methylation 
status. Values are means ± s.e.m. (d) MTT and SRB assays in the WM115 (methylated), WM793 (methylated), SK-MEL-28 (unmethylated) and 
WM266.4 (unmethylated) cell lines upon the use of BRAF or MEK inhibitors. (e) Western blot analyses of the RAS/BRAF/MEK/ERK and PI3K/AKT 
signaling pathways in TBC1D16-47KD unmethylated (U) or methylated (M) melanoma cells upon using the MEK inhibitor CI-1040. (f) Western blot 
analyses of the RAS/BRAF/MEK/ERK and PI3K/AKT signaling pathways in TBC1D16-47KD unmethylated (U) or methylated (M) melanoma cells upon 
using the BRAF inhibitor dabrafenib. Significance was determined from a 10,000-permutation t-test with Holm correction of the difference between 
growth curves. NS, nonsignificant; *P < 0.05; **P < 0.01, ***P < 0.001. Error bars show means ± s.e.m.
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WM793), were able to hyperphosphorylate AKT to escape from 
growth inhibition (Fig. 5e,f). However, this was not the case for 
the hypophosphorylated EGFR in TBC1D16-47KD-unmethylated 
cells (IGR37 and SK-MEL-28), which were unable to phosphorylate 
AKT efficiently upon administration of the MEK or BRAF inhibitor 
(Fig. 5e,f). We obtained similar results using non-serum-depleted 
medium (Supplementary Fig. 10b).
These findings suggest that TBC1D16-47KD epigenetic reactivation 
renders melanoma cells more sensitive to BRAF and MEK inhibitors, 
probably through the inability to shift to an EGFR-driven PI3K/AKT 
pathway. Notably, for those TBC1D16-47KD methylated melanomas 
that are more resistant to these drugs, the addition of an EGFR inhibi-
tor such as Iressa (gefinitib) increased the antitumoral effect of BRAF 
and MEK inhibitors (Supplementary Fig. 11a). This effect is probably 
observed because we are blocking the survival escape route mediated 
by EGFR-led PI3K/AKT signaling (Supplementary Fig. 11b). This 
combination therapy might warrant further study in BRAF and MEK 
drug-resistant melanomas.
TBC1D16-47KD demethylation predicts poor clinical outcome
The analyses of a collection of human melanomas showed a TBC1D16-
47KD unmethylated CpG island status in 41% (30 of 73) of subjects. 
Hypomethylation was associated with transcript overexpression 
(Supplementary Fig. 12a). We observed enrichment of TBC1D16-47KD 
hypomethylation in more melanoma metastases (61%, 22 of 36) com-
pared with primary melanomas (21%, 8 of 37) (Fisher’s exact test, 
P = 0.0008). We found a similar degree of TBC1D16-47KD hypometh-
ylation among the The Cancer Genome Atlas (TCGA) metastatic 
melanomas (https://tcga-data.nci.nih.gov/tcga/) (54%, 144 of 267 
cases). TCGA data confirmed the enrichment of TBC1D16-47KD 
hypomethylation in distant melanoma metastases compared with non-
disseminated primary melanomas (Mann-Whitney test, P = 0.015) 
(Supplementary Fig. 12b). Furthermore, TCGA RNA-sequencing 
data showed that TBC1D16-47KD hypomethylation was associated 
with transcript overexpression (Spearman correlation test, rho, –0.44, 
P < 0.00001) (Supplementary Fig. 12c). The study of an additional 
set of 14 paired patients’ primary and metastatic melanomas con-
firmed the enrichment of TBC1D16-47KD hypomethylation in the 
metastatic samples compared with the respective primary melanomas 
(Wilcoxon signed-rank test, P = 0.043). Paired metastases of ten 
colorectal tumors were also enriched for TBC1D16-47KD hypometh-
ylation compared with their corresponding primary tumors (Wilcoxon 
signed-rank test, P = 0.014). TCGA data set highlighted the functional 
relevance of TBC1D16-47KD hypomethylation by showing that, in the 
context of widespread blocks of DNA hypomethylation in cancer30–32, 
there was not an association between our identified demethyla-
tion event and a global DNA methylation loss within this region 
(r2 = 0.006) (Supplementary Fig. 12d). Normal melanocytes (n = 10) 
were methylated at TBC1D16-47KD. Unsupervised clustering 
analysis showed enrichment of the TBC1D16-47KD hypomethylated 
sites in our metastasis samples (Fig. 6a).
We also wondered whether TBC1D16-47KD hypomethylation 
conferred any prognostic value. TBC1D16-47KD hypomethylation 
was associated with shorter progression-free survival (PFS) (log-rank; 
P = 0.015; hazard ratio (HR) = 3.81, 95% CI = 1.17–12.35) and lower over-
all survival (OS) (log-rank; P = 0.022; HR = 4.62, 95% confidence interval 
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Figure 6 TBC1D16-47KD promoter demethylation is an independent prognostic factor for poor clinical outcome in melanoma patients.  
(a) Unsupervised clustering analysis using the CpGs located in the TBC1D16-47KD promoter shows enrichment of the hypomethylated sites in the  
metastatic melanoma samples. Green, unmethylated; red, methylated. (b) Kaplan-Meier analysis of PFS and OS in the melanoma discovery cohort 
with respect to TBC1D16-47KD methylation status. Significance of the log-rank test is shown. Results of the univariate Cox regression analysis are 
represented by the HR and 95% CI. Twelve unmethylated and 22 methylated cases had a mean PFS of 1.6 and 8.8 years (yrs), respectively.  
12 unmethylated and 24 methylated cases had a mean time OS of 2.8 and 9 years, respectively. (c) Kaplan-Meier analysis of PFS and OS among the  
melanoma validation cohort with respect to TBC1D16-47KD methylation status. Significance of the log-rank test is shown. Results of the univariate Cox 
regression analysis are represented by the HR and 95% CI. Thirty-two unmethylated and 39 methylated cases had a mean PFS of 8.1 and 11.6 years, 
respectively. Thirty-two unmethylated and 39 methylated cases had a mean OS of 4.0 and 4.9 years, respectively.
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(CI) = 1.09–19.48) (Fig. 6b). TBC1D16-47KD hypomethylation 
was also associated with lower OS in the TCGA cohort (log-rank; 
P = 0.013; HR = 1.96; 95% CI 1.14–3.36) (Supplementary Fig. 12e). 
PFS data are not available in TCGA. In a validation cohort of 71 
individuals with melanoma, TBC1D16-47KD demethylation was 
associated with metastatic melanomas (Fisher’s test; P = 0.032), 
shorter PFS (log-rank; P = 0.006; HR = 3.46, 95% CI = 1.36–8.72) 
and lower OS (log-rank; P = 0.009; HR = 4.84, 95% CI = 1.30–18.02) 
(Fig. 6c). TBC1D16-47KD hypomethylation predicted poor outcome 
across the different Breslow and ulceration statuses (Supplementary 
Fig. 12f). In this regard, TBC1D16-47KD hypomethylation was an 
independent predictor of poor PFS and OS in the multivariate analysis 
(Supplementary Table 2).
Given our findings that melanoma cells with TBC1D16-47KD 
hypomethylation were more sensitive to BRAF and MEK inhibitors, 
we wondered whether the same effect occurred in clinical samples. 
We studied the metastatic melanoma of a cohort of 33 subjects who 
were carriers of the BRAF V600E mutation and treated with either 
of the BRAF inhibitors, dabrafenib or vemurafenib. We observed a 
TBC1D16-47KD-unmethylated status in 33% (n = 11) of the melano-
mas (Supplementary Table 2). The TBC1D16-47KD unmethylated 
status was associated with complete clinical response to the BRAF 
inhibitor, whereas partial response, stable disease or progression 
occurred in individuals with TBC1D16-47KD methylation (Fisher’s 
exact test, P = 0.008) (Supplementary Table 2). Finally, we won-
dered whether TBC1D16-47KD methylation increased at the time 
of clinical progression during BRAF and MEK inhibitor treatment. 
We obtained paired melanoma samples from five individuals at the 
time of disease presentation and at relapse after therapy failure. We 
observed that initial drug response occurred in TBC1D16-47KD 
unmethylated samples, but when the melanoma relapsed,40% (2 of 5) 
of these resistant samples showed TBC1D16-47KD hypermethylation. 
Thus, the clinical data supported the experimental observations 
that TBC1D16-47KD unmethylated status increases sensitivity to 
BRAF inhibitors.
DISCUSSION
Melanoma is one of the most aggressive and therapy-resistant 
malignancies1. Many mechanisms are involved in melanoma 
progression, but dynamic epigenetic changes are likely to be critical 
contributors. Here we took an approach to identify DNA methyla-
tion events that were associated with metastasis by minimizing the 
effect of the genetic background, using paired primary and metastasis 
samples from the same individual. Using this strategy, we identified a 
hypomethylation event in TBC1D16 in the pro-metastatic melanoma 
samples. Because TBC1D16 participates in intracellular receptor 
recycling19,20, our findings reinforce the concept that melanoma is 
dependent on a high volume of vesicle trafficking19,33,34.
The contribution of TBC1D16-47KD epigenetic reactivation to 
melanoma progression can provide additional opportunities for 
therapeutic intervention related to EGFR targeting and the effects 
in RAS/BRAF/MEK/ERK and PI3K/AKT pathways. Many melano-
mas carry BRAF activating mutations that render these patients more 
sensitive to treatment with BRAF inhibitors35, whereas wild-type 
BRAF melanomas are treated by standard chemotherapy, with only 
10–20% of these individuals responding to treatment36. In addition 
to immunomodulatory treatments37, new strategies are being con-
sidered based on the knowledge that the BRAF protein modulates 
the MEK signaling cascade downstream of EGFR. In this context, 
alternative treatments using EGFR inhibitors, MEK inhibitors alone 
and various combinations with BRAF inhibitors are underway38,39. 
However, biomarkers to predict whether a patient will respond to 
these new drugs are needed. Here, we have shown that individuals 
with melanoma with TBC1D16-47KD hypomethylation have a poor 
prognosis, but at the same time, their tumors are ‘addicted’ to BRAF 
and MEK signaling and could greatly benefit from treatment with 
drugs that target this pathway.
Our findings highlight the contribution of epigenetics to the 
generation of metastasis and to the prediction of drug response. 
The example provided here of how the loss of DNA methylation 
status of an internal promoter of TBC1D16 unleashes melanoma 
progression and generates sensitivity to BRAF and MEK inhibitors 
may be helpful in clinical trials that seek to improve the outcome of 
melanoma patients.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Gene Expression Omnibus: Coordinates have been 
deposited with accession code GSE46522, DNA methylation and 
expression microarray data.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE METHODS
Human cancer cells and tissues. Human paired primary and metastasis can-
cer cell lines derived from melanoma IGR39/IGR37 and WM115/WM266.4 
were obtained from the Leibniz Institute DSMZ-German Collection of 
Microorganisms (Braunschweig, Germany) and the American Type Culture 
Collection (ATCC), respectively. The paired primary and metastasis cancer cell 
lines derived from colon (SW480 and SW620) were obtained from the ATCC. 
The breast cancer pair MDA-MB-468PT and MDA-MB-468LN was kindly 
provided by Anne Chambers (London Regional Cancer Program, London, 
Ontario, Canada). The primary melanoma cell line WM793 and the metastasis 
melanoma cell line SK-MEL-28 were obtained from the Coriell Institute for 
Medical Research and the ATCC, respectively. All cell lines were characterized 
by short tandem repeat analysis (STR) profiling (LGS Standards SLU) within 
6 months after receipt and tested on a monthly basis for mycoplasma con-
tamination. DNA from 36 additional melanoma cell lines, with previously 
known IC50 values for MEK inhibitors29, was obtained from the Wellcome 
Trust Sanger Institute (Hinxton, Cambridge, UK). To study the association of 
DNA methylation with clinical progression and OS of melanoma patients, we 
used fresh-frozen melanoma samples supplied by the Katholieke Universiteit 
Leuven (discovery cohort). As an independent validation cohort, we used pri-
mary melanomas diagnosed with Clark stage I-V and Breslow index provided 
by Lund University (Sweden). An additional set of 14 paired patients’ primary 
and metastatic melanomas was also included. To analyze the effects of DNA 
methylation with clinical response to first-line treatments in melanoma 
patients, we studied a cohort of 33 melanoma patients treated with BRAF 
inhibitors. An additional five paired melanoma samples (pre- and post-BRAF 
inhibitor therapy) were also obtained. Overall, we studied 196 melanoma 
patients with a gender distribution of 51% male and 49% female and a mean 
age of 67 ± 12 years. None of the human individual samples were excluded 
before analysis. Tissue collection and the study protocol were approved by 
the ethical committees of the FP7/2007-2013 “Target-Melanoma: Molecular 
Dissection of Melanoma Progression: An Integrated Pan-European Approach” 
consortium (#PIAPP-GA-2009-230614), the Germans Trias i Pujol University 
Hospital Biobank (BB14007), the Vall d’Hebron University Hospital Biobank 
(RE-017-VO3) and the Manchester Cancer Research Centre Biobank 
(12_JOBR_01 and 13_RIMA_01). Full informed consent was obtained from 
all subjects. DNA methylation data in melanoma were collected from the 
TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/). Patient samples were 
reversibly encoded for blinding and only the investigator responsible for each 
collection was able to decodify the cases. Sample size has been chosen consid-
ering the balance between clinical feasibility and study power, taking incidence 
of melanoma cases into account in the different stages. To ensure the statistic 
power of the results, we assumed as significant a two-tailed P value under 0.05. 
We followed the REporting recommendations for tumor MARKer prognostic 
studies (REMARK) reporting guidelines for tumor marker prognostic studies40. 
PFS and OS were determined using Kaplan-Meier plots and log-rank tests. 
Statistical analysis was performed by using SPSS for Windows.
DNA methylation arrays. We analyzed whole-genome DNA methylation in the 
three paired tumor cell lines, 10 nevi, 37 primary melanomas, and 36 melanoma 
metastases samples using the Illumina Infinium HumanMethylation450Beadchips 
as described18,41. DNA was extracted from cell lines and tissues by the phenol:
chloroform method. All DNA samples were assessed for integrity, quantity and 
purity by electrophoresis in a 1.3% agarose gel, PicoGreen quantification and 
NanoDrop measurement. All samples were randomly distributed into 96-well 
plates. We performed bisulfite conversion of 500 ng of genomic DNA using an EZ 
DNA methylation kit (Zymo Research). Bisulfite converted DNA (200 ng) was 
used for hybridization on the HumanMethylation450 BeadChip (Illumina). Raw 
fluorescence intensity values were normalized with Illumina Genome Studio 
software (V2011.1) using ‘control normalization’ with background correction. 
Normalized intensities were then used to calculate DNA methylation levels 
(beta values). Likewise, data points with statistically low power (as reported 
by detection values of P > 0.01) were designated as NA and excluded from the 
analysis. Genotyping probes present on the chip and DNA methylation probes 
overlapping with known single-nucleotide polymorphisms (SNPs) were also 
removed. Probes were considered to be in a promoter CpG island if they were 
located within a CpG island (UCSC database) and <2,000 bp away from a tran-
scription start site (outside chromosome X). We only considered CpG sites with 
a ≥70% change in CpG methylation level between primary and metastases sites, 
and the differential CpG methylation primary and metastasis had to occur in 
the three tumor types studied.
Bisulfite sequencing and pyrosequencing. For primer sequences please refer 
to Supplementary Table 3. We used the EZ DNA Methylation Gold kit (Zymo 
Research, Orange, CA, USA) for genomic DNA bisulfite conversion. For bisulfite 
sequencing, a minimum of eight single clones was interrogated for each sample 
and the methylation frequency was calculated in each case, as described42. DNA 
methylation in clinical samples was studied by pyrosequencing on bisulfite-
treated DNA extracted from formalin-fixed paraffin-embedded (FFPE) samples. 
Pyrosequencing reactions and quantification of DNA methylation were per-
formed in a PyroMark Q96 System version 2.0.6 (Qiagen) including appropriate 
controls as described7. Specific primers were designed using the MethylExpress 
program (Applied Biosystems) for bisulfite sequencing and PyroMark Assay 
Design Software (Qiagen, version 2.0.01.15) for pyrosequencing to examine 
the methylation status of particular CG sites covering the candidate genes pro-
moter regions.
Expression analysis. Total RNA samples of paired melanoma cell lines IGR39 
and IGR37 were extracted and sent to the IRB Functional Genomic Core 
External Service (Barcelona). Once samples had been reversed-transcribed and 
labeled, they were hybridized onto Affymetrix GeneChip Human Genome U133 
Plus 2.0 arrays. Hybridization, washing, staining and scanning were performed 
using Affymetrix GeneChip system instruments and protocols. For breast and 
colon cancer cell lines, expression data were obtained from the Gene Expression 
Omnibus (GSE11683, GSE10843 and GSE57083). For qRT–PCR experiments, 
total RNA was extracted using Trizol reagent and retrotranscribed using the 
ThermoScript RT-PCR system (Invitrogen). The reaction was carried out fol-
lowing the methods for use of SYBR Green (Applied Biosystems), and B2M, 
GAPDH and ACTB were used as housekeeping genes to enable normalization. 
For primer sequences please refer to Supplementary Table 3. We performed 
reactivation treatments with the demethylating agent 5-aza-2′-deoxycytidine 
(AZA; Sigma) at 0.5 µM for 72 h. For immunoblotting assays, we extracted 
total protein using RIPA (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and 
EGTA, 1% NP40, 0.5% of sodium deoxycholate, 0.1% of SDS, and protease and 
phosphatase inhibitors from Roche). All the antibodies used in this study are 
described in Supplementary Table 3.
Short hairpin interference and ectopic expression assays. For shRNA and 
cloning sequences please refer to Supplementary Table 3.Three and four differ-
ent shRNAs were designed over the TBC1D16-45KD/47KD and 86KD mRNA, 
respectively, to target melanoma, breast and colon TBC1D16-expressing cells. 
shRNA against the MSS2 yeast protein (not present in mammals) was used 
as scrambled. All annealed shRNA oligos were ligated into pLVX-shRNA2 
plasmid, purchased from Clontech, using BamH1 and EcoR1 restriction sites. 
Each shRNA-encoding plasmid (10 µg) was mixed with 7.5 µg of ps-PAX2 and 
2.5 µg of PMD2.G plasmid in 1 ml JetPRIME buffer and 50 µl of JetPRIME 
(Polyplus-transfection S.A., Illkirch, France). After 10 min of RT incubation, 
the transfection mix was added drop-wise to a 10-cm dish containing 10 ml 
of DMEM and 293T cells at 80% confluence. After 48 h, viral supernatant was 
recovered and 0.45-µm filtered. After 48–72 h, cells were checked for infection 
efficiency. For transduction efficiencies lower than 95%, cells grown and green 
positive cells were isolated by flow cytometry. After cell sorting, 10–20 clones 
were isolated by limiting dilution, checked for silencing, and finally 5–10 of 
the best clones were mixed as a pool to perform the in vitro and in vivo experi-
ments to avoid the cloning bias-effect. If the infection efficiency was higher 
than 95%, we worked with the cells as a pool. We also engineered the construct 
corresponding to TBC1D16-47KD ORF so that the three target regions of the 
three shRNAs used have been mutated to render the mRNA insensitive to 
shRNA-mediated depletion. To construct the RNAi-insensitive TBC1D16 
overexpressing construct, we used a three-step PCR-based strategy in which 
mutant sites at third codon-positions were introduced by the PCR primers. The 
mutations introduced are synonymous changes and encode the same TBC1D16 
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wild-type protein. Both the wild-type cDNA (shRNA-sensitive) and the mutant 
cDNA (shRNA-insensitive) were tested in parallel in MDA-MB-468LN cells 
stably expressing each shRNA. Additionally, we carried out cotransfection 
experiments in MDA-MB-468LN and IGR37 cell lines in which the wild-type 
cDNA was fused to a FLAG tag (pLVX-ZsGreen1, Clontech) and the mutated 
cDNA was fused to a HA tag (pLVX-tdTomato, Clontech). For ectopic 
overexpression experiments, TBC1D16-47KD cDNA was amplified from IGR37 
using specific primers with end adaptors containing EcoRI and NotI sequences 
and a Kozak sequence. The PCR product was verified by Sanger-sequencing 
and ligated into pLVX-ZsGreen1 plasmid from Clontech using EcoRI and NotI 
restriction sites. The 293T transfections and cell infections (IGR39, WM793 
and WM115) were performed following the same procedures as for shRNA 
constructs. TBC1D16-45KD cDNA was obtained using TBC1D16-47KD cDNA 
as a template following a three-step PCR based strategy.
In vitro proliferation and colony formation. Cell proliferation was determined 
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. The proliferation of the cells indicated in the figures were quantified for 6 d, 
staining the cells with MTT for 3 h and blocking the reaction adding lysis buffer 
(HCl 20 mM, acetic acid 2.5%, SDS 20%, dimethylformamide 50%, pH 4.7). 
Measurements were done at 560 nm after overnight incubation at 37 °C. 
Colony-formation assay was performed by seeding 300 cells onto 12-well 
plates and maintaining them on DMEM medium. After 2 weeks, cells were 
MTT-stained and fixed, and colonies were quantified using Fiji software.
Mass spectrometry analysis and validation. Once we had infected the IGR37 
cells with TBC1D16-47KD-FLAG (DYKDDDDK)-expressing vector, we per-
formed the immunoprecipitation as follows: 2 mg of total protein extract was 
recovered in 1 ml of RIPA (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA and 
EGTA, 1% NP40, 0.5% of sodium deoxycholate, 0.1% of SDS, and protease and 
phosphatase inhibitors from Roche) and put on ice. After cleaning the mem-
brane residues, overnight precleaning was done with magnetic beads (Dynabeads 
M-280 sheep anti-mouse IgG, Invitrogen) at 4 °C. Anti-FLAG antibody (30 µg) 
from Sigma (F1804) was incubated with 300 µl of magnetic beads overnight at 
4 °C in BSA 0.5%. Beads were removed from the protein solution, and magnetic 
beads with anti-FLAG antibody were recovered. Following bead cleaning, eluted 
proteins were reduced with β-mercaptoethanol at 70 °C for 10 min. Samples were 
loaded and run on a gradient NuPAGE Novex 4–15% Bis-Tris Polyacrylamide 
Gel (Life Technology). Bands were identified incubating the gel overnight with 
EZBlue Gel Staining Reagent (G1041, Sigma). Single bands were excised and sent 
to the external proteomics service of the Barcelona Parc Scientific (Spain). Mass 
spectrometry was performed in a NanoAcquity (Waters) HPLC coupled to an LTQ 
OrbitrapVelos mass spectrometer (Thermo Scientific). Data analysis was carried 
out in the LTQ OrbitrapVelos. Peptide masses were measured in the Orbitrap at a 
resolution of 60,000 (m/z: 300–1700). Most abundant peptides were selected from 
each MS scan and fragmented in the linear ion trap with helium as the collision 
gas. All results were filtered so only proteins identified with high confidence pep-
tides (FDR ≤ 0.01) and with at least three peptides were included. Finally, results 
were filtered by Homo sapiens. For co-immunoprecipitation validation, IGR37 
TBC1D16-NH2-FLAG cells were grown at 70% confluence. Cells were detached 
using a scraper. Total protein extract (1 mg) was prepared in RIPA. Samples were 
precleared using Dynabeads M-280 Sheep Anti-Mouse IgG (Invitrogen), overnight 
at 4 °C in rotation. Antibodies against the candidate proteins were pre-incubated 
with beads overnight at 4 °C in rotation. For colocalization analysis, the cells were 
cultured directly on poly-L-lysine coverslips and fixed with 4% paraformaldehyde 
for 30 min. Cells were permeabilized with 0.1% Triton X-100 for 10 min and 
blocked with 2% blocking reagent (Roche) for 1 hour. The immunostainings were 
performed for 16 h at 4 °C. The coverslips were then mounted on glass slides with 
Mowiol. Multicolor immunofluorescence images were captured, and the images 
were analyzed with the plugin Intensity Correlation Analysis (ImageJ) to calculate 
the Manders’ R overlap colocalization coefficient.
GAP assays. FLAG-TBC1D16-47KD protein was purified from HEK293T cells. 
Recombinant RAB5C GTPase (100 pmol) (Origene, TP310698) was loaded 
with [γ−32P]GTP for 10 min at 25 °C and desalted on PD-SpinTrapTM G-25 
columns (GE Healthcare, # 28-9180-04) to remove free nucleotide. GAP assay 
was then conducted in 1× assay buffer (20 mM HEPES, KOH pH 7.6, 50 mM KCl, 
5 mM MgCl2, 0.1 mg/ml BSA) containing 0.3 µM RAB5C-GTP and increasing 
concentrations of TBC1D16-47KD at 25 °C. Aliquots were removed at various 
times and quenched by vortexing the reaction mixture with 700 µl of a sus-
pension of 70 mg/ml charcoal in 20% (vol/vol) ethanol, 0.2 M HCl and 0.1 M 
KH2PO4. The quenched samples were spun to pellet the charcoal and 32Pi in 
the supernatant was analyzed by counting Cerenkov radiation in a scintillation 
counter (Beckman Coulter).
EGFR time course assay. Parental cell lines, IGR37 scramble and IGR37 shRNA-1 
and shRNA-3 were grown to 80% confluence and then serum-starved overnight, 
incubating at 37 °C. During the last 4 h, 25 µg/ml cycloheximide was added to 
the medium to prevent protein synthesis. Cells were placed on ice for 30 min, 
20 ng/ml of human EGF was added, and cells were kept on ice for an additional 
30 min. Subsequently, cells in six-well plates were moved to a 37 °C incubator 
for the indicated times. The cells were then washed three times with cold PBS 
and lysed in ice-cold RIPA buffer.
xCELLigence real-time cell invasion assay. The invasion assays were performed 
in CIM-16 plates with 8-µm-pore membranes (ACEA Biosciences). Wells were 
coated with 30 µl of 5% Matrigel (BD Bioscience) and allowed to gel at 37 °C 
and 5% CO2 for 4 h. After 4 h, the lower chamber wells were filled with 160 µl of 
10% FBS containing medium and the top chamber wells with 40 µl of serum-free 
medium. The two portions were assembled together and allowed to equilibrate 
for 1 h at 37 °C and 5% CO2. Cells were incubated for 16 h in 0.05% FBS media; 
for seeding, the cells were rinsed with PBS, trypsinized and resuspended in 
serum-free medium. A total of 4 × 104 cells and wells for IGR39, IGR37 and 
SKMEL28 and 12 × 104 for WM266.4, WM793 and WM115 were seeded onto 
the top chamber of CIM-16 plates and placed into the xCELLigence system for 
data collection after background measurement. The xCELLigence software was 
set to collect impedance data every 15 min during 72 h. The cell index represents 
the capacity for cell invasion, whereas the slope of the curve can be related to 
the invasion velocity.
Cell viability assays. Cells were seeded in either 96-well microplates at ~15% 
confluence in medium with 10% FBS, penicillin and streptomycin. The optimal 
cell number for each was determined to ensure that each one was in growth 
phase at the end of the assay. After overnight incubation, cells were treated with 
18 concentrations of each compound (twofold dilution series) and then returned 
to the incubator for assay after 72 h. The media of treatments involving lentiviral 
depletions or overexpressions was always supplemented with EGF according to 
the EGFR modulation induced by TBC1D16-47KD protein. Cells were plated 
and incubated overnight with serum-free medium before treatment. The day 
after, drugs were dispensed at different concentrations and after 1 h, EGF was 
added to a final concentration of 10 ng/ml. After 72 h of incubation at 37 °C, cell 
viability was determined by the MTT and the sulforhodamine B (SRB) assays.
Preparation of protein lysates for western blot analysis of MEK and BRAF 
inhibition. Cells were treated with the MEK inhibitor CI-1040 or BRAF inhibi-
tor dabrafenib in 10% FBS supplemented medium or in low-serum conditions. 
For the serum-depleted assay, cells were washed in medium containing 0.1% FBS 
(FBS) and incubated in this medium for 48 h. Drugs (5 µM) or DMSO (0.05%) 
were added directly to this medium, and 45 min later, EGF was added at a final 
dose of 10 ng/ml. Cells were harvested after 30 min of EGF stimulation. Protein 
lysates were prepared from cells at 80% confluence. Total protein was extracted 
adding Laemmli buffer 1× directly to the plates after washing the cells twice 
with cold PBS. The lysates were processed using a Branson Ultrasonics 25/450 
Sonifier and boiled at 100 °C for 5 min. Protein concentrations were determined 
by Lowry procedures and western blot was performed using NuPAGE Novex 
4–12% Bis-Tris gels and standard techniques.
Mouse studies. Mice tumor growth and metastasis experiments were performed 
as described43. Tumor cells lines IGR37 scramble and IGR37 shRNA-1 (1 × 106 
cells diluted in 200 µl of Matrigel BD) were grafted subcutaneously in anesthe-
tized athymic nu/nu mice (Harlan Laboratories), each cell type in one side of 
the mice back (n = 10). Tumor volumes were estimated each three days from 
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two-dimensional caliper measurements using the equation V = (π/6) × L × W2, 
where V = volume (mm3), L = length (mm), and W = width (mm), and reported 
as volume mean ± s.d. for each mouse group. Tumor weights were obtained after 
death and small pieces of tumor were stored to confirm the transfection stability 
and TBC1D16-47KD silencing. After subcutaneous assay, additional subcuta-
neous tumors were used for the orthotopic model. Once the tumor had grown 
to 600–800 mm3, it was cut into 3 × 3 mm3 pieces and maintained in DMEM 
supplemented medium with 10% FBS and penicillin/streptomycin. Those frag-
ments with macroscopically low or absent levels of necrotic areas were selected 
for orthotopic implantation. A cutaneous back shave biopsy of normal skin was 
done by removing a rhomboid area of around 6 mm2 (4 × 3 mm), and then a 
small fragment of solid tumor tissue was anchored with a prolene 7.0 suture 
to the edge of the skin, fixing the tumor at four anchored sites coinciding with 
each corner. To improve the implantation process, the anchored-skin tumor was 
protected making a skin fold that was fixed with three points with 5.0 silk sutures 
or two surgery staples. Thus, eight animals were implanted for each cell line 
tumor derived, and the orthotopic tumor was allowed to grow for several weeks. 
Mice were weighed, and the tumor width (W) and length (L) measured every 
3 d. Tumor volume was estimated according to the formula V = π/6 × L × W2. 
The animals were maintained in a sterile environment; their cages, food and 
bedding were sterilized by autoclaving. All experiments with mice were approved 
by the Institutional Animal Care and Use Committee. Following the orthotopic 
growth assay, for subgroups of eight IGR37 scramble and eight IGR37 shRNA-1 
mice, the tumor was surgery removed by an excisional surgery and the skin 
closed by 5.0 silk sutures suture, and mice kept alive for up to 3 months. Mice 
were monitored over this period for the presence of transit metastases following 
back and axillary lymph node affection. Finally, after the mice were sacrificed, 
the lung, liver and brain were examined by the pathologist for the presence of 
distal metastases. For each tumor, small fragments of 2–5 mm3 obtained in 
the previous pre-experiment were reimplanted orthotopically by a cutaneous 
shave biopsy, in the normal skin of 20 athymic nu/nu mice aged 4–5 weeks. 
These tumors in addition to those derived from IGR39 were then used in tumor 
drug response assays. When tumors reached a size of 200–400 mm3 mice, 
15 mice harboring homogeneous skin tumors were randomized into two groups 
and treated with dabrafenib or vehicle alone (DMSO) by daily oral gavage of 
0.5% hydroxypropylmethylcellulose (Sigma-Aldrich), 0.2% Tween 80 in pH 8.0 
distilled water at 30 mg/kg for 12 d. For the metastasis model without the influ-
ence of tumor burden, 1.5 × 106 IGR37 and WM115 cells were injected into the 
spleen of 20 mice (10 mice for each condition). To avoid local tumor growth, 
the spleens were removed 48 h after cell injection. Mice were sacrificed when 
first symptomatologies that suggested liver and/or lung dysfunction appeared. 
Hepatic and lung metastases were examined macroscopically and microscopi-
cally following H&E stain tissue staining. The total number of metastatic nodes 
from several randomly chosen areas of each liver was counted for the analy-
sis. Additional tumor growth assay were performed in melanoma, breast and 
colon cancer models. All animal specimens used for the experiments were male, 
except for the breast cancer cell lines MDA-MB-468PT and MDA-MB-468LN, 
which were female. None of the mice samples were excluded before analysis. 
Mice samples were reversibly encoded for blinding. All animal experiments 
were approved by the IDIBELL Ethical Committee (no. AAALAC-3880) and 
performed in accordance with guidelines stated in The International Guiding 
Principles for Biomedical Research involving Animals, developed by the Council 
for International Organizations of Medical Sciences (CIOMS)44.
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